pathway is another important cell-proliferation pathway downstream of EGFR that is frequently activated in cancer. Although mutations in Ras oncogenes do not seem to coexist with EGFR mutations ...

The IPASS (Iressa Pan-Asia Study) is the first large randomized clinical trial that compared first-line EGFR TKI therapy with chemotherapy. 1 In this study, 1,217 Asian non-smokers or former light ...

Alternative RTK pathways that are activated following EGFR inhibition is another area ... and as yet undiscovered mutations. Advancing our knowledge of specific cellular and molecular mechanisms ...

EGFR mutation-positive NSCLC refers to a subtype of lung cancer based on specific mutations ... novel targeted therapies earlier in the treatment pathway to address resistance and improve survival ...

The FDA has approved a novel combination therapy using Lumakras® (sotorasib) and Vectibix® (panitumumab) for adults with KRAS ...

The FDA also approved Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to identify KRAS G12C-mutant patients.

J&J is trying to supplant AstraZeneca's blockbuster Tagrisso, a once-daily pill that has transformed the treatment of non-small cell lung cancer with EGFR mutations. It remains to be seen how many ...